Telix Pharmaceuticals has announced the dosing of the first patient in Part 2 of its ProstACT Global Phase 3 study, which evaluates the prostate cancer therapy candidate TLX591 in patients with metastatic castration-resistant prostate cancer. This trial is notable for combining a PSMA-targeted radio antibody drug conjugate therapy with standard care treatments. The study is expanding globally, with recruitment ongoing in several countries, and plans to submit data to the FDA to further expand the trial in the U.S. This milestone is significant for Telix’s prostate cancer therapeutics pipeline and may enhance its industry positioning by potentially offering a new treatment option with fewer adverse effects compared to existing therapies.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.